FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addre <u>Halstead Mi</u>	, ,	Person*		uer Name and Tick a-Cellular Th		,		tionship of Reporting all applicable) Director	• • • • • • • • • • • • • • • • • • • •			
	Last) (First) (Middle) C/O INTRA-CELLULAR THERAPIES, INC.				action (Month/	Day/Year)	X	Officer (give title below) EVP and Ge	Other below neral Counse	'		
(Street) NEW YORK NY 10016 (City) (State) (Zip)				mendment, Date of	Original Filed	l (Month/Day/Year)	6. Indiv Line) X	′				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		

	(Month/Day/Year)	if any (Month/Day/Year)	Code (Instr. 8)		Disposed Of (D) (Instr. 3, 4 and 5)			Beneficially Owned Following	(D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(1115tt. 4)
Common Stock	12/31/2019		A ⁽¹⁾		7,807	A	\$0.00	7,998	D	
Common Stock	01/02/2020		S ⁽²⁾		1,623	D	\$31.83(3)	6,375	D	
Common Stock	01/02/2020		S ⁽²⁾		4,959	D	\$32.43(4)	1,416	D	
Common Stock	01/02/2020		S ⁽²⁾		1,200	D	\$33.23 ⁽⁵⁾	216	D	
Common Stock	01/02/2020		S ⁽²⁾		25	D	\$34.3	191	D	
Common Stock	01/03/2020		M		5,298	A	(6)	5,489	D	
Common Stock	01/03/2020		M		16,160	A	(6)	21,649	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date,		4. Transaction Code (Instr. 8)		umber vative urities uired or oosed o) (Instr. and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(7)	01/03/2020		M			5,298	(8)	(8)	Common Stock	5,298	\$0.00	0	D	
Restricted Stock Units	(7)	01/03/2020		M			16,160	(9)	(9)	Common Stock	16,160	\$0.00	16,160	D	

Explanation of Responses:

- 1. Represents shares issued upon the vesting of performance stock units.
- 2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2019. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$31.56 to \$31.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$32.00 to \$32.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.03 to \$33.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 6. Restricted stock units convert into common stock on a one-for-one basis.
- 7. Each restricted stock unit represents a contingent right to receive one share of common stock.
- 8. On January 3, 2017, the reporting person was granted 15,893 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
- 9. On January 3, 2018, the reporting person was granted 48,480 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.